← All trials
NCT05277922
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 28, 2022
- Primary completion
- May 11, 2022
- Completion date
- May 20, 2022
- First posted
- Mar 14, 2022
- Last posted
- Nov 14, 2022
- Enrollment
- 5
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Vicore Pharma ABLead sponsor
- Clinical Trial Consultants ABCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.